Sep 13, 2021 / 04:00PM GMT
Operator
Good afternoon, and welcome to the Theratechnologies KOL webinar on tesamorelin for the treatment of nonalcoholic steatohepatitis. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Theratechnologies' website following the conclusion of today's event. I'd now like to turn the call over to our host, Paul Lévesque, President and Chief Executive Officer of Theratechnologies. Paul, please go ahead.
Paul Lévesque - Theratechnologies Inc. - President, CEO & Director
Good afternoon. I would like to welcome everyone today for joining us. I believe we have a very good program for you highlighting the NASH disease area and Theratechnologies' Phase III development program evaluating tesamorelin for the treatment of NASH. The first part will be a panel discussion with leading NASH KOL, Dr. Rohit Loomba, Dr. Stephen Harrison and Dr. Steve Grinspoon followed by an audience Q&A session.
Joining the panel for the Q&A sessions will be Christian Marsolais, Theratechnologies' Chief
Theratechnologies Inc Discuss on Treatment of NASH Key Opinion Leader Webinar Transcript
Sep 13, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers